Characteristics and outcomes of 231 COVID-19 cases admitted at a tertiary facility in India: An observational cohort study

Kumar, Rohit; Bhattacharya, Baidurya; Meena, Ved Prakash; Aggarwal, Anivita; Tripathi, Manasi; Soneja, Manish; Mittal, Ankit; Singh, Komal; Gupta, Nishkarsh; Garg, Rakesh; Ratre, Brajesh Kumar; Kumar, Balbir; Bhopale, Shweta; Tiwari, Punit; Verma, Ankit; Bhatnagar, Sushma; Wig, Naveet; Guleria, Randeep

doi:10.4103/jfmpc.jfmpc_1198_20

Cited by 7 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indirect evidence on the question of susceptibility can also be gathered by comparing prevalence of diabetes in COVID-19 patients with that in the general population. The estimates have varied from 7.2-27.3% in various studies from China, Italy, USA and India, which are lesser, equal or greater than the background prevalence of diabetes in these countries [ 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 ]. Therefore, based on these data, it is difficult to draw any firm conclusion with regards to disease susceptibility.…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 Seroprevalence in Individuals With Type 1 and Type 2 Diabetes Compared With Controls

et al. 2022

View full text Add to dashboard Cite

Objective Data for association between diabetes and SARS-CoV-2 susceptibility are conflicting. We aimed to evaluate this association using an analytical cross-sectional study design. Methods Study participants were recruited from endocrine clinics of our hospital and belonged to three groups: group 1 (T1DM), group 2 (T2DM), and group 3 (controls). All participants submitted blood samples for SARS-CoV-2 S1/S2 IgG antibody test (Diasorin Liaison), and were interviewed for history of documented infection. Results We evaluated total of 643 participants [T1DM: 149, T2DM: 160, Control: 334; mean age: 37.9±11.5 years]. A total of 324 (50.4%) participants were seropositive. Seropositivity rate was significantly higher in T1DM (55.7% vs. 44.9%, p=0.028) and T2DM (56.9% vs. 44.9%, p=0.013) groups, then control group. Antibody levels in seropositive T1DM and T2DM participants were not significantly different from seropositive controls. On multivariable analysis, low education status [OR: 1.41 (95% CI, 1.03, 1.94), p=0.035], diabetes [OR: 1.68 (95% CI, 1.20, 2.34), p=0.002], and overweight/obesity [OR: 1.52 (95% CI, 1.10, 2.10), p=0.012] showed significant association with SARS-CoV-2 seropositivity. The association between diabetes and SARS-CoV-2 seropositivity was found to further increase in participants with co-existing overweight/obesity [adjusted OR, 2.63 (95% CI, 1.54, 4.47, p<0.001]. Conclusions SARS-CoV-2 seropositivity, assessed before the onset of national vaccination program, was significantly higher in participants with T1DM and T2DM, compared to controls. The antibody response did not differ between seropositive participants with and without diabetes. These findings point towards an increased SARS-CoV-2 susceptibility for patients with diabetes, in general, without any differential effect of the diabetes type.

show abstract

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 Seroprevalence in Individuals With Type 1 and Type 2 Diabetes Compared With Controls

et al. 2022

View full text Add to dashboard Cite

show abstract

“…[13][14][15][16][17][18][19] Results of our study shows that more males (76.41%) are infected as compared to females which are consistent with the results of other studies reported in literature ranging between 60-93%. [20][21][22][23][24][25]…”

Section: Discussionmentioning

confidence: 99%

“…No. of males (%) Chen 20 55.59 67.9 Kumar et al 21 39.89 78.3 Kayina 22 50.7 68.1 Bhandari 23 35.42 60.91 Mohan 24 40.1 93.1 Bairwa 25 45.15 68.71…”

Section: Study Mean Age (Years)mentioning

confidence: 99%

Outcome of intensive care unit admitted COVID-19 patients with co-morbid conditions requiring ventilator support

Purushothaman

Dhotre²,

Sharma³

et al. 2023

Int J Adv Med

View full text Add to dashboard Cite

Background: The characterization of intensive care unit (ICU) admitted COVID-19 patients with co-morbid conditions requiring ventilator support can help investigators worldwide to prepare for emergency situation arising at the time of spread of disease. The objective of our study is to analyse the outcome of ICU admitted COVID-19 patients with co-morbid conditions. Methods: Post ethics committee approval for multiple centers, data of 212 consecutive discharged and death COVID-19 confirmed ICU patients were included and analyzed. These patients of all age groups and genders were admitted in Bhaktivedanta Hospital and Research Institute, Mira Road, Mumbai, Maharashtra, India which is a dedicated COVID hospital from March 2020 to November 2020. Results: Of the total 212 ICU patients, 17 (9%) cases were moderate, 195 (91%) were severe cases as per CT severity score grading, median duration of stay in the hospital was 9 (37%) days. Diabetes mellitus was the leading co-morbid condition with frequency of 27.8% followed by ischemic heart disease (IHD) (5.6%), chronic kidney disease (CKD) (5.1%), asthma (3.77%) and chronic obstructive pulmonary disorder (COPD) (0.94%). Conclusions: Not all patients with co-morbid conditions progress towards poor lung function. IHD is the worst prognostic indicator for progressing towards poor lung function as compared to diabetes, CKD and COPD.

show abstract

“…3 Our data shows that more males (71.68%) are infected as compared to females which is consistent with the result of other studies reported earlier with ranges between 60-93%. [4][5][6][7][8][9] The presence of comorbidities such as diabetes mellitus (DM), hypertension (HTN), chronic obstructive pulmonary disease (COPD) or old age leads to poorer clinical outcomes in COVID-19 patients. [10][11][12][13][14] Our finding are similar to these studies Table 3.…”

Section: Discussionmentioning

confidence: 99%

Multi-center study to analyse outcome of integrated treatment approach in COVID-19 patients

Purushothaman

Dhotre

Vanarase

et al. 2023

Int J Community Med Public Health

View full text Add to dashboard Cite

Background: This study presents the outcome of integrated treatment approach based on government mandated standard allopathic treatment along with alternatives in COVID-19 patients. The aim of our study was to investigate the outcome of treatment strategy, co-morbid status, recovery and mortality rate of COVID-19 patients at Bhaktivedanta Hospital and Research Institute. Methods: Post ethics committee approval for multiple centers, data for 1049 COVID-19 patients (RTPCR confirmed cases) of all age groups and genders which were admitted in a dedicated covid hospital from March 2020 to November 2020 was analysed retrospectively. Results: This study highlights the management of COVID-19 patients with an integrated approach. In our cohort with 36.7%, 44.70 %, 18.58% of mild, moderate and severe cases respectively, mortality rate was only 3.43% of total positive patients admitted at our hospital. Conclusions: We emphasize that even in healthcare facilities with limited resource and poor infrastructure and lack of ICU facilities, clinical observation-based management can help to reduce mortality considerably. Unique features of our study include use of progesterone as an immune modulator, use of dual antiviral agents and use of age-related lower limit of oxygen saturation.

show abstract

Characteristics and outcomes of 231 COVID-19 cases admitted at a tertiary facility in India: An observational cohort study

Cited by 7 publications

References 24 publications

SARS-CoV-2 Seroprevalence in Individuals With Type 1 and Type 2 Diabetes Compared With Controls

SARS-CoV-2 Seroprevalence in Individuals With Type 1 and Type 2 Diabetes Compared With Controls

Outcome of intensive care unit admitted COVID-19 patients with co-morbid conditions requiring ventilator support

Multi-center study to analyse outcome of integrated treatment approach in COVID-19 patients

Contact Info

Product

Resources

About